|
1.
|
|
18 p, 8.9 MB |
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma
/
Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ;
Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ;
González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Vall d'Hebron Institut d'Oncologia) ;
Jauset, Toni (Vall d'Hebron Institut d'Oncologia) ;
Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Vall d'Hebron Institut d'Oncologia) ;
Grueso, Judit (Vall d'Hebron Institut d'Oncologia) ;
Nonell, Lara (Vall d'Hebron Institut d'Oncologia) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway-the most predominantly mutated pathway in this disease-turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. [...]
2023 -  10.1101/gad.350078.122
Genes & Development, Vol. 37 (april 2023) , p. 303-320
|
|
|
2.
|
|
10 p, 912.2 KB |
Pharmacokinetic analysis of omomyc shows lasting structural integrity and long terminal half-Life in tumor tissue
/
Beaulieu, Marie-Eve (Peptomyc SL) ;
Martínez-Martín, Sandra (Peptomyc SL) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Castillo Cano, Virginia (Peptomyc SL) ;
Massó Vallés, Daniel (Peptomyc SL) ;
Foradada Felip, Laia (Peptomyc SL) ;
López-Estévez, Sergio (Peptomyc SL) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Thabussot, Hugo (Peptomyc SL) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
MYC is an oncoprotein causally involved in the majority of human cancers and a most wanted target for cancer treatment. Omomyc is the best-characterized MYC dominant negative to date. In the last years, it has been developed into a therapeutic miniprotein for solid tumor treatment and recently reached clinical stage. [...]
2023 - 10.3390/cancers15030826
Cancers, Vol. 15, Issue 3 (February 2023) , art. 826
|
|
|
3.
|
|
21 p, 11.5 MB |
MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding
/
Massó Vallés, Daniel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Beaulieu, Marie-Eve (Hospital Universitari Vall d'Hebron) ;
Jauset González, Toni (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Giuntini, Fabio (Vall d'Hebron Institut d'Oncologia) ;
Zacarías-Fluck, Mariano F (Vall d'Hebron Institut d'Oncologia) ;
Foradada Felip, Laia (Hospital Universitari Vall d'Hebron) ;
Martínez-Martín, Sandra (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Serrano, Erika (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ;
Castillo Cano, Virginia (Hospital Universitari Vall d'Hebron) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ;
Morcillo, Miguel Ángel (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (Espanya)) ;
Alzrigat, Mohammad (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ;
Mahmoud, Loay (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ;
Luque-García, Antonio (Vall d'Hebron Institut d'Oncologia) ;
Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ;
Guzman, Marta (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Larsson, Lars-Gunnar (Karolinska Institutet (Suècia). Department of Microbiology, Tumor and Cell Biology) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Soucek, Laura (Institució Catalana de Recerca i Estudis Avançats)
While MYC role in metastasis has been long controversial, this manuscript demonstrates that MYC inhibition by either transgenic expression or pharmacologic use of the recombinantly produced Omomyc miniprotein exerts antitumor and antimetastatic activity in breast cancer models in vitro and in vivo, suggesting its clinical applicability.
2022 - 10.1158/2767-9764.CRC-21-0103
Cancer Research Communications, Vol. 2 (february 2022) , p. 110-130
|
|
|
4.
|
|
|
5.
|
|
2 p, 456.4 KB |
Live or Die : Choice Mechanisms in Stressed Cells
/
Cecconi, Francesco (Department of Biology, University of Rome "Tor Vergata", 00133 Rome, Italy) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Taub, Dennis D. (Center for Translational Studies, Medical Services, VA Medical Center, Department of Veteran Affairs) ;
Ziparo, Elio (Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Section of Histology and Medical Embryology, Sapienza University of Rome)
2015 - 10.1155/2015/454863
Mediators of Inflammation, Vol. 2015 (october 2015)
|
|
|
6.
|
|
17 p, 2.0 MB |
Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells : Towards the validation of a tumor suppressor role for the Max homodimers
/
Maltais, Loïka (Université de Sherbrooke. Département de Biochimie) ;
Montagne, Martin (Université de Sherbrooke. Département de Biochimie) ;
Bédard, Mikaël (Université de Sherbrooke. Département de Biochimie) ;
Tremblay, Cynthia (Université de Sherbrooke. Département de Biochimie) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Lavigne, Pierre (Université de Sherbrooke. Département de Biochimie)
It is classically recognized that the physiological and oncogenic functions of Myc proteins depend on specific DNA binding enabled by the dimerization of its C-terminal basic-region-Helix-Loop-Helix-Leucine Zipper (b-HLH-LZ) domain with that of Max. [...]
2017 - 10.1371/journal.pone.0174413
PloS one, Vol. 12 (March 2017) , art. e0174413
|
|
|
7.
|
|
|
8.
|
|
19 p, 1.3 MB |
Blocking Myc to treat cancer : reflecting on two decades of Omomyc
/
Massó Vallés, Daniel (Peptomyc S.L.) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. [...]
2020 - 10.3390/cells9040883
Cells, Vol. 9, Issue 4 (April 2020) , art. 883
|
|
|
9.
|
|
10 p, 3.3 MB |
The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets
/
Zacarías-Fluck, Mariano F. (Vall d'Hebron Institut d'Oncologia) ;
Jauset González, Toni (Hospital Universitari Vall d'Hebron) ;
Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Kaur, Jastrinjan (Vall d'Hebron Institut d'Oncologia) ;
Casacuberta-Serra, Sílvia (Hospital Universitari Vall d'Hebron) ;
Massó Vallés, Daniel (Vall d'Hebron Institut d'Oncologia) ;
Serrano del Pozo, Erika (Vall d'Hebron Institut d'Oncologia) ;
Martín-Fernández, Génesis (Vall d'Hebron Institut d'Oncologia) ;
González-Larreategui, Íñigo (Vall d'Hebron Institut d'Oncologia) ;
López-Estévez, Sergio (Hospital Universitari Vall d'Hebron) ;
Brown-Swigart, Lamorna (Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California) ;
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia) ;
Whitfield, Jonathan R. (Vall d'Hebron Institut d'Oncologia) ;
Madan, Babita (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ;
Virshup, David M. (Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School) ;
Evan, Gerard I (Department of Biochemistry, University of Cambridge) ;
Soucek, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Zacarías-Fluck, et al identify and validate the Wnt receptor Fzd9 as a key effector of Myc-Wnt signaling cross-talk in a mouse model of Myc-driven pancreatic insulinomas. The huge cadre of genes regulated by Myc has obstructed the identification of critical effectors that are essential for Myc-driven tumorigenesis. [...]
2021 - 10.26508/lsa.201900490
Life Science Alliance, Vol. 4 (march 2021)
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
